Cancer Immunotherapy in India

Dendritic Cell Therapy is a kind of cancer vaccine made from your own blood. In the lab, your dendritic cells are primed and replicated to expose your specific cancer to your immune system. The 'trained' cells would increase the ability of your body to work against the cancer by concentrating the dendritic cells of your body on correctly identifying the cancer of your body as a threat and then reintroducing those cells into your system.

A clean blood sample is taken. In the lab, monocyte cells are washed and exposed to various growth factors in order to transform into dendritic cells. Dendritic cells are "primed" by being exposed to specific cancer antigens. After 7 days in the laboratory, the patient can receive qualified and concentrated dendritic cells with a simple injection or infusion. Cancer cells are stimulated and bound by cytotoxic T-cells, causing them to die (apoptosis).

Theoretically, all cancers can be treated. So far, treatments have shown benefits for cancers like prostate, colorectal, ovarian, breast, melanoma, pancreatic, and renal cell cancers. These cancers have higher success rates with treatment.

Dendritic cell therapy usually doesn't cause big problems. Some patients might feel a bit feverish for a day or two after getting the vaccine. Others might feel tired or weak for a few days. So far, no patients have had any severe allergic reactions.

When the sickness isn't getting worse; when the person doesn't have the illness anymore but there's a chance it could come back; to provide comfort and relief; when the patient needs immune therapy along with chemo and radiation; when everything else has been tried; or when the person's body isn't strong enough for chemo or radiation treatment.

Cancer immunotherapy is an approach that aims to help the body's own immune system recognize and act against cancer cells, rather than attacking the cancer directly.

Categories include checkpoint inhibitor drugs, cell-based approaches using immune cells, engineered monoclonal antibodies, and cancer vaccines, each working through a different mechanism.

NK cell treatment is one example of a cell-based immunotherapy approach, using immune cells with a natural ability to act against abnormal cells.

No. Applicability depends heavily on the specific cancer type, stage, and the patient's overall health. Some cancers have well-established immunotherapy options; others do not.

Not necessarily. It is typically considered alongside, not automatically instead of, standard oncology treatment, and is coordinated with the patient's existing oncology team.

This is assessed during a free medical evaluation, where the clinical team reviews the diagnosis and staging against available options.

No. Outcomes vary significantly by cancer type, stage, and individual factors, and are not guaranteed. See our safety and guarantees page.

They are complementary, not interchangeable. Cancer immunotherapy supports function and recovery directly, while Exosome Therapy for Retinal Detachment targets vision loss from a detached retina at the cellular level; some patients use both as part of one care plan.

Yes. Cancer immunotherapy and Exosome Therapy for Retinopathy address different aspects of recovery, and the two are often coordinated within the same care plan for patients dealing with retinal blood-vessel damage, often diabetes-related, when both are clinically appropriate.

Some do. Patients researching nerve pain and numbness from diabetes sometimes explore Exosome Therapy for Diabetic Neuropathy as a complementary option alongside cancer immunotherapy, with the combination assessed case-by-case during a free medical evaluation.

It can be. Exosome Therapy for Muscular Dystrophy is a separate regenerative option some patients consider alongside cancer immunotherapy when managing progressive muscle weakness, coordinated by the clinical team rather than self-directed.

They are complementary, not interchangeable. Cancer immunotherapy supports function and recovery directly, while Exosome Therapy for Osteoporosis targets low bone density and fracture risk at the cellular level; some patients use both as part of one care plan.

Yes. Cancer immunotherapy and Exosome Therapy for Parkinson’s Disease address different aspects of recovery, and the two are often coordinated within the same care plan for patients dealing with tremor, rigidity, and movement symptoms, when both are clinically appropriate.

Some do. Patients researching autoimmune joint inflammation sometimes explore Exosome Therapy for Rheumatoid Arthritis as a complementary option alongside cancer immunotherapy, with the combination assessed case-by-case during a free medical evaluation.

It can be. Exosome Therapy for Sciatic Nerve Injury & Sciatica is a separate regenerative option some patients consider alongside cancer immunotherapy when managing sciatic nerve pain radiating down the leg, coordinated by the clinical team rather than self-directed.

They are complementary, not interchangeable. Cancer immunotherapy supports function and recovery directly, while Exosome Therapy for Shoulder Injury targets rotator cuff and shoulder joint damage at the cellular level; some patients use both as part of one care plan.

Yes. Cancer immunotherapy and Exosome Therapy for Spinal Cord Injury address different aspects of recovery, and the two are often coordinated within the same care plan for patients dealing with loss of motor or sensory function after cord damage, when both are clinically appropriate.

Some do. Patients researching motor-neuron loss and progressive weakness in SMA sometimes explore Exosome Therapy for Spinal Muscular Atrophy as a complementary option alongside cancer immunotherapy, with the combination assessed case-by-case during a free medical evaluation.

It can be. Exosome Therapy for Sports Injuries is a separate regenerative option some patients consider alongside cancer immunotherapy when managing soft-tissue and joint injuries from athletic activity, coordinated by the clinical team rather than self-directed.

They are complementary, not interchangeable. Cancer immunotherapy supports function and recovery directly, while Exosome Therapy for Systemic Lupus targets autoimmune inflammation affecting multiple organs at the cellular level; some patients use both as part of one care plan.

Yes. Cancer immunotherapy and Exosome Therapy for Wound Healing address different aspects of recovery, and the two are often coordinated within the same care plan for patients dealing with slow-healing or chronic wounds, when both are clinically appropriate.